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Abstract
Background Dengue is a major emerging public health
concern in tropical and subtropical countries. Severe den-
gue can lead to hospitalisation and death. This study was
performed to assess the economic burden of hospitalisa-
tions for dengue from 2007 to 2011 in three French terri-
tories of the Americas where dengue is endemic (French
Guiana, Martinique and Guadeloupe).
Methods Data on dengue-associated hospitalisations were
extracted from the French national hospital administrative
database, Programme de Me´dicalisation des Syste`mes
d&Information (PMSI). The numbers of stays and the cor-
responding number of hospitalised patients were deter-
mined using disease-specific ICD-10 codes. Associated
hospital costs were estimated from the payer perspective,
using French official tariffs.
Results Overall, 4183 patients (mean age 32 years; 51 %
male) were hospitalised for dengue, corresponding to 4574
hospital stays. In nearly all hospital stays (98 %; 4471), the
illness was medically managed and the mean length of stay
was 4.3 days. The mean cost per stay was €2522, corre-
sponding to a total hospital cost of €11.5 million over the 5
years assessed. The majority of hospitalisations (80 % of
patients) and associated costs (75 % of total hospital costs)
were incurred during two epidemics.
Conclusion Severe dengue is associated with significant
hospital costs that escalate during outbreaks.
Keywords Dengue  Hospitalisation cost  Economic
burden  French Guiana  Guadeloupe and Martinique
JEL Classification I1 Health/I120 Health production
Introduction
Dengue is an infectious disease caused by dengue viruses,
transmitted to humans by mosquitoes (Aedes aegypti and
Aedes albopictus) [1, 2]. Infection with dengue may be
asymptomatic in some cases, or may manifest as a range of
symptoms from self-limited dengue fever lasting 2 to
7 days to the more severe life-threatening dengue haem-
orrhagic fever with shock syndrome including severe
bleeding and/or severe organ impairment, and death. Sev-
ere dengue is a medical emergency requiring immediate
hospital management including intravenous fluid replace-
ment, oxygen administration and vital signs surveillance.
There is no specific antiviral treatment for dengue: current
practice focuses on the alleviation of symptoms. Most
patients recover fully from dengue, but some may experi-
ence fatigue and depression lasting several weeks [3, 4].
At present, prevention or reduction of dengue virus
transmission depends entirely on the control of the mos-
quito vectors or interruption of human-vector contact.
These methods alone have thus far demonstrated to be
insufficient to control the disease [1]. In 2009, the World
Health Organization (WHO) estimated that approximately
2.5 billion people lived within the hundred inter-tropical
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countries where the disease is endemic. With a worldwide
incidence estimated at 50–100 million cases per year,
dengue is the most rapidly spreading viral disease, with
incidence rates having increased 30-fold in the last
50 years [2]. More recently, Bhatt et al. [5] using carto-
graphic modelling approaches with data from a combina-
tion of published literature and online resources for the
period 1960 to 2012, estimated that there may be ap-
proximately 390 million dengue infections (symptomatic
and asymptomatic) per year, of which 96 million (67–136)
experienced manifest disease (of any severity). Severe
dengue causes an estimated 500,000 hospitalisations every
year [2] and approximately 20,000 deaths annually [6].
Dengue is also an increasing public health concern in
the Americas where there has been a 4.6-fold increase in
the number of cases over the last three decades (from ap-
proximately 1 million cases during the 1980s to 4.7 million
during 2000–2007) [7]. With an ever increasing number of
cases, the economic burden inflicted on those populations
in endemic areas is substantial [8–10]. In the Americas, the
economic burden associated with dengue was estimated to
be US$2.1 billion [11]. French Guiana, Martinique and
Guadeloupe (three French territories in the Americas) are
dengue endemic areas with cyclical epidemics every
3–5 years. The availability of an exhaustive official French
hospital database represents a unique opportunity to assess
the burden of dengue in these territories where the
population is approximately 1 million (around 400,000 in
Guadeloupe, 380,000 in Martinique and 250,000 in French
Guiana) [12]. To date, only one publication has reported
costs associated with dengue in these three territories, but
the costs reported were based on extrapolation from other
countries in the Americas [11]. The objective of the present
study was to assess the cost associated with hospitalisation
for dengue in French Guiana, Martinique and Guadeloupe
from 2007 to 2011.
Methods
Data sources
The French Medical Information System (Programme de
Me´dicalisation des Syste`mes d&Information, PMSI) is an
exhaustive medico-administrative hospital discharge data-
base that covers all public and private hospitals in France
as well as those in the French Territories [13–15]. Diag-
noses identified during admission are coded using the In-
ternational Classification of Diseases, 10th revision (ICD-
10) by the physician. PMSI includes a compilation of
standard discharge summaries (‘‘Re´sume´ Standard de
Sortie’’, RSS) for every admission. Anonymised data
(‘‘Re´sume´ Standardise´ Anonymise´’’, RSA) with limited
socio-demographic information (gender, age, residence
code) and medical information on the main diagnosis that
led to hospital admission, the nature of treatments received
and examinations carried out, underlying comorbidities and
possible complications, are made available for epi-
demiologic studies. Each patient&s stay is classified by Di-
agnosis Related Group (DRG) (Groupe Homoge`ne de
Se´jours) according to information documented by the
physician.
The economic burden of hospitalised cases would be
expected to be well documented within the PMSI database
because since the introduction of a DRG-based prospective
payment system (the ‘‘Tarification a` l’Activite´’’) in 2005,
the PMSI database has been used as the basis for the
funding of services in all hospitals, with each hospital re-
ceiving DRG-based payments according to the national
tariff. Thus, data extracted from this database is exhaustive
(all public and private hospitals are included and no sam-
pling is done) and of high quality, with limited coding
errors. In addition, the FICHCOMP (‘‘FiICHier
COMPle´mentaire’’) database contains a restricted list of
‘‘expensive drugs’’ that are fully reimbursed, and has been
available since 2008 for public hospitals only.
Data collection of dengue stays
All hospital stays in the French territories of French
Guiana, Martinique and Guadeloupe from 2007 to 2011
(data from more recent years were not available at the
time of analysis) with a primary or associated dengue-
specific code were selected from the PMSI database using
the ICD-10 codes A90* or A91* [‘‘Dengue fever (clas-
sical dengue)’’ or ‘‘Dengue haemorrhagic fever (severe
dengue)’’, respectively]. In this first data collection, we
gathered hospital stays for confirmed dengue or suspected
dengue. In a second step we assessed a medical inter-
pretation in order to select the confirmed dengue cases
completed by PMSI guidelines. In this second step, we
used the PMSI guidelines to firstly select confirmed
dengue cases based on ICD-10 diagnosis code A90* or
A91* in position of primary diagnosis. When the ICD-10
diagnosis code A90* or A91* is observed in position of
associated diagnosis, the medical interpretation is abso-
lutely necessary. Based on the medical interpretation of
PMSI database stays and particularly the primary diag-
nosis, the dengue was confirmed or not.
A conservative approach was used by selecting only
those hospital stays that had a primary diagnosis of dengue
or had a direct link with dengue. One of the authors (LT)
manually assessed all hospital stay cases that had an as-
sociated link to dengue (i.e. where dengue was a secondary
diagnosis) to exclude those where dengue was considered
doubtful.
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For patients hospitalised for dengue, gender, age and
comorbidities, type of management received (medical,
surgical or exploratory), type of stay (conventional inpa-
tient stays or short outpatient stays), and length of stay, as
well as whether stays occurred partly, or completely, in the
emergency or an intensive care unit, and occurrence of
related deaths were collected. Conventional inpatient stays
include day hospitalisations defined as an admission of 2 or
more days’ duration, whereas short stays include day
hospitalisations. Since patients may have several hospital
stays during the year, the overall number hospitalised at
least once over a given period could be obtained by linking
all hospital stays with anonymised patient identification
numbers based on the patient’s social security number, date
of birth and gender.
Economic burden of dengue hospitalisation
Costs were estimated from the social security payer per-
spective, i.e. Ministry of Health public fund. Ambulatory
costs and indirect costs related to productivity loss were not
considered in the present study. Hospital-associated costs
were calculated using official DRG tariffs and ‘‘expensive
drug’’ tariffs for each year considered. DRG tariffs repre-
sent the willingness-to-pay by the national health insurance
and not the hospital cost production. DRG tariffs include
medical and related procedures, nursing care, treatments
(except specific expensive drugs), drugs used, food and
accommodation, and investment costs for hospitalised pa-
tients. Additional cost per day of hospitalisation in emer-
gency or an intensive care unit was added to DRG tariffs,
when appropriate. For private hospitals, physician’s fees
were also added to the DRG tariffs; physicians are reim-
bursed on a fee-for-service basis (source: ENCC 2010).
Costs are presented as mean cost per stay, mean cost per
patient and total cost per year for the three French terri-
tories in the Americas. All costs are presented in euros (€).
Results
A total number of 6273 hospital stays for dengue were
identified in the PMSI database between 2007 and 2011,
including 4750 stays (76 %) that occurred in French Gui-
ana, Martinique or Guadeloupe (Fig. 1). Of the hospital
stays in the three French territories, 176 (4 %) were con-
sidered to be doubtful for dengue and were excluded. The
remaining 4574 hospital stays constituted the base case of
the present analysis. Overall, 4183 patients were hospi-
talised for dengue during the study period: 622 (15 %)
patients in French Guiana; 2231 (53 %) in Martinique; and
1354 (32 %) in Guadeloupe. A patient may have several
dengue hospitalisations in different territories, resulting in
a non-arithmetic total of patients over all the three terri-
tories. Three peaks in the overall number of hospital stays
were observed during the study period (Fig. 2): 28 % of
hospital stays occurred in 2007, 11 % in 2009 and 51 % in
2010. Among the total number of patients hospitalised in
the three French territories during the study period, patients
hospitalised for dengue represented 0.81 % (n = 1184) of
patients in 2007, 0.17 % (n = 237) in 2008, 0.29 %
(n = 445) in 2009, 1.35 %(n = 2204) in 2010 and 0.08 %
(n = 129) in 2011.
Males represented 51 % (n = 2146) of cases, and the
overall mean age was 32 (SD 23) years. Children and
young adults (aged younger than 19 years) accounted for
43 % (1962) of stays. More than half of stays (55 %; 2533)
had no underlying comorbidity. Over the 2021 stays oc-
curred with at least one comorbidity, sickle-cell disease
was recorded in 6 % (126) of stays. Most hospital stays
[60 % (2734); range 44 % (140/318) for the year 2008 to
68 % (327/483)] for the year 2009 were initially admitted
via the emergency department (Fig. 3), representing 2734
stays. Only 147 (3 %) hospital stays were initially admitted
via the intensive care unit. Forty (1 %) patients died during
their stay. Conventional inpatient dengue stays accounted
for 84 % (3839 stays) of all hospital stays. The median
length of dengue stay was 3 days (range from 0 to more
than 20 days) and the mean length of stay was 4.3 days
(SD 7). The length of dengue stay was less than 5 days in
69 % (3174 stays) of stays, and was similar year on year
(Fig. 4).
In nearly 4471 dengue stays (98 %), the illness was
medically managed, with surgical intervention recorded
in\1 % (26) of stays.
Economic burden of dengue hospitalisation
Table 1 summarises the mean cost (based on national DRG
tariffs) per stay, mean annual cost per patient and the total
annual cost of hospitalisation for dengue for the three
French territories. The mean cost per stay during the study
was estimated at €2522 (SD €3707). The total hospi-
talisation cost amounted to €11.5 million, of which, 27, 10
and 52 % of these costs were incurred in 2007, 2009 and
2010, respectively. The total cost of expensive drugs used
in treatment between 2008 and 2011 was €143,453, of
which 94 % (€135,144) of the cost was incurred in 2010. In
2010, three drugs counted for 92 % of the expensive drug
costs for that year: €56,334 (42 %) for the use of Benefix
(coagulation factor IX recombinant), €43,552 (32 %) for
Tegeline (human immunoglobulin) and €24,537 (18 %)
for Novoseven (coagulation factor VIIa recombinant).
The mean cost per patient was estimated at €2758 (SD €
9605), range €2588 (SD €5040) in 2007 to €4138 (SD €
11,920) in 2011.




The present study was designed to estimate the economic
burden of hospitalisation related to dengue infections in
three French territories of the Americas where dengue is
endemic, between 2007 and 2011. The total hospitalisation
cost reached €11.5 million over the 5-year period.
What is already known on this topic
In terms of the average cost per stay, our results appear to
be consistent with those presented by Shepard et al. [11]
who estimated these at US$3460, US$3430 and US$4052
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between 2007 and 2011  
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in three overseas French 
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Fig. 1 Flow-chart of stays
selected for the analysis. A90*
and A91* correspond to ICD-10
codes for dengue fever
(classical dengue) and dengue
haemorrhagic fever,
respectively. *A given patient
may be hospitalised in more
than one department over the
period
Fig. 2 Annual number of
hospitalisations for dengue from
2007 to 2011 in each of the
three French territories*. *A
given patient may be
hospitalised in more than one
department over the period
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Fig. 3 Percentage of stays where patients were admitted via the
emergency or intensive care unit by year
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per hospitalised dengue case in 2010 (equivalent to €2494,
€2473 and €2921 assuming US$1 = €0.72, 2014 exchange
rate) in French Guiana, Martinique and Guadeloupe, re-
spectively, versus an average of €2522 across the three
territories in the present study.
What this study adds
We observed that the annual number of hospital stays for
dengue in Martinique and Guadeloupe appeared to mirror
each other over the study period, with peaks in stays ob-
served during 2007 and 2010. This may be explained by the
relative proximity of these territories to each other and to
the dengue epidemics observed in those years in these two
territories. In French Guiana, the annual number of hospital
stays peaked in 2009; again consistent with the occurrence
of a dengue epidemic in that region during that year.
Overall, the hospitalisation costs incurred during these
dengue epidemics accounted for about 90 % of the overall
costs over the study period.
The present study underlines the central role of the
emergency department in the management of dengue.
Overall, 60 % of hospitalisations for dengue between 2007
and 2011 were initially admitted via the emergency de-
partment. Emergency departments allow both triage of
patients who do not require hospitalisation and for those
who do in severe cases. Unfortunately, the PMSI database
does not record information on patients who attend the
emergency department but who do not require subsequent
hospitalisation. It would be interesting to analyse the
number of patients who attend the emergency department
for dengue but who do not require subsequent hospi-
talisation and their related associated costs, especially
during an epidemic. Epidemics represent significant chal-
lenges for health-care providers with regard to delivering
care to a large number of patients in a short period of time,
as well as identifying those at risk of developing severe
dengue requiring hospitalisation [1]. For instance, in
Martinique in the 2010 outbreak, it was observed that
dengue represented more than 10 % of the total emergency
Fig. 4 Distribution of the length of stay by year
Table 1 Cost per stay, annual cost per patient and total annual costs from the social security perspective
Number of
stays
Stays admitted via the intensive care
unit* (%)
Mean (±SD) cost per
stay (€)




2007 1297 4 2362 ± 2454 2588 ± 5040 3,064,199
2008 318 1.6 2765 ± 2682 3710 ± 14,649 879,370
2009 483 1.9 2312 ± 2074 2509 ± 4080 1,116,874
2010 2335 2.9 2545 ± 3707 2696 ± 4215 5,942,788
2011 141 9.2 3786 ± 11,441 4138 ± 11,920 533,866
2007–2011 4574 3.2 2522 ± 3707 2758 ± 9605 11,537,098
* With financial supplement
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admissions, while this usually represents less than 1 %,
which could lead to a possible saturation of the emergency
department [16].
Although outbreaks were associated with qualitative
changes in the management and in the profile of hospi-
talised patients, this was not reflected in the cost per den-
gue case. For instance, the use of expensive drugs was
predominant during the 2010 outbreak, which accounted
for 94 % of the overall costs for these expenses. In addi-
tion, the proportion of patients hospitalised in intensive
care units was also increased during the 2007 and 2010
epidemics. Nonetheless, these variations in costs had a
negligible impact on the average annual costs per case
(Table 1). However, as the PMSI database is based on the
collection of coding added by various health professionals,
it is possible that coding bias may have contributed to this
observation. At the opposite end, the cost per stay was
highest in 2011, a dengue non-epidemic year. The higher
costs per stay observed in 2011 may be attributed, in part,
to the higher rate of admission to the intensive care unit
compared to other years (9.2 % with n = 13 stays versus
an over mean at 3.2 % with n = 147 stays). This obser-
vation may simply reflect ‘‘classic disease management’’
during a non-epidemic period following an epidemic,
where the few patients with disease receive intensive
treatment and monitoring—whereas during epidemics, in
order to avoid intensive care unit saturation, a more rig-
orous selection of severe cases with complications may
occur.
Limitations of this study
In addition to the direct costs associated with dengue,
which escalate during epidemics, dengue prevention mea-
sures such as vector control through use of larvicides and
fumigation as well as education, media, and community
campaigns, incur additional costs that are not captured
within the PMSI database. The additional costs incurred for
prevention measures have been reported for both the 2007
epidemic in Guadeloupe and the 2010 epidemic in Mar-
tinique. During the epidemic of 2010 in Martinique,
€60,000 and €120,000 were spent on insecticides and
communication, respectively, and extra funding of
€100,000, given by the government, was used mainly for
educational campaigns [16]. In Guadeloupe, the cost of a
communication campaign for the 2007 epidemic was re-
ported as €130,424, of which, €98,542 was paid by the
national government with the remainder paid by various
external partners, private organisations or municipalities
[17]. Of note, the cost of the communication campaign
represented 20 % of the global governmental budget for
communication in Guadeloupe for 2007.
In order to estimate the global economic burden of
dengue, costs outside the hospital setting associated to
ambulatory care (pre- and post-hospitalisation costs in-
curred by a dengue hospital case, and the ambulatory
costs incurred by a dengue ambulatory case) and costs
related to productivity losses would need to be assessed.
Indeed, the majority of dengue infections are treated in an
ambulatory setting. In the Americas [11] ambulatory cases
(with ambulatory care only) accounted for 73 % of the
overall total direct costs for the management of dengue,
but with high variability between regions. Taking into
account this breakdown of costs, the total direct costs
associated with dengue in the three French territories
could reach €42.6 million (€11.5 million for hospitalised
cases and €31.1 million for ambulatory cases, assuming
that ambulatory cases represent 73 % of the total). This
total direct cost could increase by estimating also the
ambulatory care pre- and post- hospitalisation. Indirect
costs associated with loss of work or school absenteeism
for the patient or the caregiver are also considerable. An
estimated 60 % of the total costs associated with dengue
in the Americas corresponded to indirect costs, mostly
related to productivity losses [11]. In addition, recent
evidence indicates that dengue causes a substantial re-
duction in quality of life during infection that lasts longer
than the duration of fever [3, 4, 19–21]. Chronic fatigue
may negatively impact on daily activities and ability to
work for up to 2 years after infection [3, 4], with asso-
ciated productivity losses that may be substantial.
Conclusions
The present analysis is a first step in the estimation of the
global economic burden of dengue in French Guiana,
Martinique and Guadeloupe, three French territories of the
Americas where dengue is endemic. To present the com-
plete economic burden, ambulatory costs would also need
to be collected as well as indirect costs associated with
dengue infections. However, the costs of hospitalisation
reported in our study already highlight the economic im-
pact of dengue, especially during epidemics. Further
studies analysing the cost of dengue are needed considering
that several vaccine candidates [21] and other prevention
and control technologies are currently under development
[22–25]. These studies will help determine the most effi-
cient strategy in the management of dengue.
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